Sharecast News
04 May, 2021 07:44 04 May, 2021 07:44

AstraZeneca's Forxiga gets US approval for chronic kidney disease

astrazeneca soumet a l ue une demande pour une usine de vaccins aux pays bas 20210411183427

AstraZeneca said on Tuesday that Farxiga has been approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes.

The pharmaceuticals giant said the approval by the US Food and Drug Administration is "the most significant advancement in the treatment of chronic kidney disease in more than 20 years".

The approval was based on positive results from the DAPA-CKD Phase III trial and the decision follows the Priority Review designation granted by the FDA earlier this year.

Mene Pangalos, executive vice president of BioPharmaceuticals R&D, said: "We've shown impressive efficacy for Farxiga in type-2 diabetes, heart failure with reduced ejection fraction and, most recently, chronic kidney disease and we are thrilled to be able to bring this medicine to millions of patients in the US."


News Source: © 2021 Web Financial Group (UK) Limited. All rights reserved and terms of use apply.

Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.

 

Important Legal Notice about News Sources

Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news articles and we may not share the views of the author or publisher.

We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.